Maine 2023-2024 Regular Session

Maine Senate Bill LD1829

Introduced
4/27/23  
Refer
4/27/23  
Engrossed
3/27/24  

Caption

An Act to Direct the Maine Prescription Drug Affordability Board to Assess Strategies to Reduce Prescription Drug Costs and to Take Steps to Implement Reference-based Pricing

Companion Bills

No companion bills found.

Previously Filed As

ME LD697

An Act to Direct the Maine Prescription Drug Affordability Board to Assess Strategies to Reduce Prescription Drug Costs and to Take Steps to Implement Reference-based Pricing

ME LD1816

An Act Requiring Reference-based Pricing to Reduce Prescription Drug Costs

ME SB212

Enacting the prescription drug cost and affordability review act to establish the prescription drug pricing board and prescription drug affordability stakeholder council to review the cost of prescription medications and establish upper payment limits for certain prescription drugs.

ME SB01202

An Act Concerning Prescription Drug Affordability.

ME SB1533

Prescription drugs; costs; affordability division

ME SB604

Related To Prescription Drug Costs.

ME HB18

Related To Prescription Drug Costs.

ME SF2238

A bill for an act relating to prescription drug affordability, including the creation of a prescription drug affordability board.

ME HF2408

A bill for an act relating to prescription drug affordability, including the creation of a prescription drug affordability board.

ME SF264

A bill for an act relating to prescription drug affordability, including the creation of a prescription drug affordability board.

Similar Bills

HI HB18

Related To Prescription Drug Costs.

HI SB604

Related To Prescription Drug Costs.

RI H7877

Prescription Drug Cost Protection

RI S0098

Prescription Drug Cost Protection

RI S2076

Prescription Drug Cost Protection

RI H5431

Prescription Drug Cost Protection

OK SB734

Prescription drugs; prohibiting certain entities from purchasing prescription drugs in excess of certain rate. Effective date.

RI S0468

Prohibits the state, participating ERISA, or any health plan from purchasing referenced drugs for a cost higher than the referenced rate.